Stem weighs sale, merger, and other options ahead of Q3 earnings
- Stem (STEM) announced on Monday that its board had launched a review of strategic alternatives to maximize shareholder value, ahead of the company’s third-quarter 2026 earnings report on November 5.
- The options include a potential sale of the company or assets, a merger, refinancing, recapitalization, or continuing as a standalone business.
- The company hired Guggenheim Securities as a financial advisor and two law firms to advise on the review.
- The board has not set a timeline, and there is no guarantee the review will result in a transaction.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.